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Background: The vaginal microbiota of healthy women consists of a wide variety of anaerobic and aerobic
bacterial genera and species dominated by the genus Lactobacillus. The activity of lactobacilli helps to maintain the
natural healthy balance of the vaginal microbiota. This role is particularly important during pregnancy because
vaginal dismicrobism is one of the most important mechanisms for preterm birth and perinatal complications. In
the present study, we characterized the impact of a dietary supplementation with the probiotic VSL#3, a mixture of
Lactobacillus, Bifidobacterium and Streptococcus strains, on the vaginal microbiota and immunological profiles of
healthy women during late pregnancy.
Results: An association between the oral intake of the probiotic VSL#3 and changes in the composition of the
vaginal microbiota of pregnant women was revealed by PCR-DGGE population profiling. Despite no significant
changes were found in the amounts of the principal vaginal bacterial populations in women administered with
VSL#3, qPCR results suggested a potential role of the probiotic product in counteracting the decrease of
Bifidobacterium and the increase of Atopobium, that occurred in control women during late pregnancy. The
modulation of the vaginal microbiota was associated with significant changes in some vaginal cytokines. In
particular, the decrease of the anti-inflammatory cytokines IL-4 and IL-10 was observed only in control women but
not in women supplemented with VSL#3. In addition, the probiotic consumption induced the decrease of the
pro-inflammatory chemokine Eotaxin, suggesting a potential anti-inflammatory effect on the vaginal immunity.
Conclusion: Dietary supplementation with the probiotic VSL#3 during the last trimester of pregnancy was
associated to a modulation of the vaginal microbiota and cytokine secretion, with potential implications in
preventing preterm birth.
Trial registration: ClinicalTrials.gov NCT01367470Background
The vaginal microbiota of healthy women consists of a
wide variety of anaerobic and aerobic bacterial genera
and species dominated by the facultative, microaero-
philic anaerobic genus Lactobacillus [1]. The activity of
lactobacilli helps to maintain the natural healthy balance
of the vaginal microbiota. This role is particularly im-
portant during pregnancy because abnormalities in vagi-
nal communities, such as bacterial vaginosis (BV) and* Correspondence: b.vitali@unibo.it
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reproduction in any medium, provided the oraerobic vaginitis (AV), have been claimed as important
mechanisms responsible for preterm birth and perinatal
complications [2].
The association of lower genital tract infection with an
increased risk of preterm delivery and preterm rupture
of the fetal membranes has recently attracted great inter-
est in the pathogenesis of such infection-related
mechanisms [3,4]. Earlier studies showed an increased
rate of prematurity in women with BV, an alteration of
the endogenous vaginal microbiota associated with
decreased levels of hydrogen peroxide-producing Lacto-
bacillus species [4-6]. The mechanisms linking BV with
preterm delivery have not been fully identified, but locald. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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http://www.biomedcentral.com/1471-2180/12/236immune response is hypothesized to be crucial. Despite
the notion that BV is a non-inflammatory condition, evi-
dence exists that demonstrates altered levels of certain
pro-inflammatory cytokines in women with BV [7,8].
Parturition is characterized by cervical ripening and
myometrial maturation with subsequent uterine contrac-
tions leading to cervical dilatation and birth [9]. The
process of labor displays many of the hallmarks of in-
flammation. Acute inflammatory features, such as
increased influx of leucocytes and elevated expression of
pro-inflammatory cytokines, have been observed in cer-
vical tissues and fetal membranes during both term and
preterm labor [10-12].
A potentially novel way to protect against infection-
mediated preterm birth is to use probiotic bacteria, espe-
cially lactobacilli. Probiotics, defined as “live microorgan-
isms which, when administered in adequate amounts,
confer a health benefit on the host” [13], are being studied
for their ability to replenish vaginal lactobacilli and modu-
late immunity [14-16]. In addition, administration of pro-
biotics to the mother during pregnancy and breast-feeding
has been described by some studies as a safe and effective
mode of enhancing the immunoprotective potential of the
breast milk and preventing atopic eczema in the infant
[17,18].
In recent years, culture-independent techniques based
on the analysis of rRNA gene sequences have been devel-
oped, providing powerful tools to reveal the phylogenetic
diversity of the microorganisms found within vaginal
microbiota and to understand community dynamics
[19-24]. In particular, PCR-denaturing gradient gel elec-
trophoresis (PCR-DGGE) has been successfully used to
identify the bacterial composition of different ecological
niches, including the vaginal microbiota [22,25,26]. Real-
time PCR is a powerful technique for the quantitative
analysis of specific microbial populations belonging to
complex ecosystems [22,27,28]. Specific primers can be
used to focus the quantitative analysis on a particular
genus, species or strain of interest.
Several bacterial species are known to colonize both
the gastrointestinal and the reproductive tract, and the
rectum has been suggested to play an important role as
a source or reservoir for organisms that colonize the va-
gina [15,29]. On this basis, the aim of the present study
was to evaluate the impact of a dietary supplementation
with the probiotic product VSL#3, a mixture of Lactoba-
cillus, Bifidobacterium and Streptococcus strains, on the
vaginal microbiota and immunological profiles of asymp-
tomatic healthy women during late pregnancy. The dy-
namics of the vaginal bacterial communities prior and
after probiotic ingestion were assessed by PCR-DGGE
and real-time PCR, while the modulation of the cytokine
secretion in vaginal fluids was measured by LuminexW
Immunoassay. Although previous studies demonstratedthe therapeutic efficacy of VSL#3 in the management of
gastrointestinal disorders, especially inflammatory bowel
disease [30], as well as the ability of the VSL#3 strains to
colonize the gut environment [31] and to modulate the
immune response of the colonic mucosa [32], this is the
first study that investigates the indirect effects of this
probiotic formula on the vaginal microbiota.
Results
Bacterial population profiling with PCR-DGGE
PCR-DGGE analysis with universal primers for bacteria
(HDA1-GC/HDA2) was used to investigate: (i) the sta-
bility of the predominant vaginal bacterial communities
over a period of 4 weeks in the last trimester of preg-
nancy, from the 33rd (W33) to the 37th (W37) week of
gestation, and (ii) the influence of the oral consumption
of the probiotic VSL#3 from W33 to W37 on the pre-
dominant vaginal microbiota (Figure 1).
DGGE band profiles displayed a relatively low com-
plexity for both probiotic (P) and control (C) groups, as
assessed by the richness index. Mean values of the rich-
ness index were 6.6 at both W33 and W37 for C group
and shifted from 8.4 (W33) to 7.4 (W37) for P group
without significant variations between W33 and W37.
Pearson correlation was used to calculate the similarity
index (SI) between DGGE patterns related to the time
points W33 and W37 for each pregnant woman (Table 1).
The SI median values of P group and C group were 73%
and 79%, respectively. In particular, 3 women belonging to
P group (N. 2, 9 and 10) and only one woman belonging
to C group (N. 24) showed SI values lower that 50%. For
each woman, significant differences between DGGE pro-
files related to W33 and W37 were searched by Wilcoxon
Signed Rank Test. No significant variations were detected
between W33 and W37 in control women. Significant dif-
ferences (P < 0.05) were found for 5/15 (33%) women
belonging to P group (N. 4, 5, 9, 10, 11). Interestingly,
women N. 9 and 10 were the same presenting SIs < 50%.
These data suggested a potential role of the probiotic for-
mula in modulating the vaginal bacterial communities.
The peak heights of the DGGE densitometric curves were
analyzed using the Wilcoxon Signed Rank Test in order to
search for significant differences in single species abun-
dances between W33 and W37. No significant changes in
species abundance were found for both P and C groups,
even in women N. 4, 5, 9, 10, 11.
Cluster analysis showed that the DGGE profiles related
to the time points W33 and W37 clustered together for
all the control women, except for the woman N. 24
(Figure 1). Four supplemented women (N. 2, 9, 10 and
15) showed W33 and W37 DGGE profiles not closely
related. However, the DGGE patterns of the majority of
the women administered with VSL#3 grouped according


































































































































































































































































































































































































Figure 1 (See legend on next page.)
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Figure 1 PCR-DGGE analysis with universal primers for bacteria. Analysis was conducted on the vaginal samples collected at 33rd (W33) and
37th (W37) week of gestation from 15 women supplemented with the probiotic VSL#3 [(P) N. 1–15] and 12 control women [(C) N. 16–27]. N:
woman number; W: week of gestation; T: type of supplementation. (A) PCR-DGGE fingerprints. M, external reference marker. (B) Dendrogram of
the DGGE profiles shown in panel A. Pearson correlation was used to calculate the similarity in DGGE profiles.
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http://www.biomedcentral.com/1471-2180/12/236the inter-individual variability was higher than the vari-
ability induced by the probiotic supplementation.
Because of the importance of lactobacilli in the estab-
lishment of a healthy vaginal environment [2], DGGE
analysis with Lactobacillus-specific primer set (Lac1/
Lac2-GC) was also carried out. This analysis allowed us
to investigate the variations in lactobacilli population oc-
curring physiologically from W33 and W37 and poten-
tially associated with the VSL#3 intake (Figure 2).Table 1 Similarity index (SI) of DGGE profiles related to
W33 and W37 obtained with universal (HDA1/HDA2) and
Lactobacillus-specific (Lac1/Lac2) primers





























27 84.5 86.3Richness indexes ranged from 5.7 (W33) to 5.4 (W37)
for P group and from 6.3 (W33) to 6.8 (W37) for C group.
Mean values of SI were 79% and 80% for P and C groups,
respectively (Table 1). Only 2 women included in P group
showed SIs < 50% (N. 1 and 15). Wilcoxon Signed Rank
Test highlighted significant differences between DGGE
profiles related to W33 and W37 for women N. 7 and 10,
accounting for 13% of women included in P group. Com-
paring this percentage with the 33% obtained by DGGE
analysis with HDA1-GC/HDA2 primer set, the probiotic
intake seemed to have a more extended impact on total
bacteria than lactobacilli. Notably, only for woman N. 10,
significant differences were found between W33- and
W37-related DGGE patterns for both HDA1-GC/HDA2
and Lac1/Lac2-GC primer sets.
The peak height analysis by Wilcoxon Signed Rank
Test allowed us to identify a band, denominated L16
(Figure 2), which significantly changed after probiotic
supplementation. Sequencing of the DNA extracted
from this band revealed 100% homology with L. helveti-
cus strains. The nucleotide sequence of this DGGE frag-
ment was deposited in DDBJ Nucleotide Sequence
Database under the accession number AB571603. L. hel-
veticus was found to be a representative species within
lactobacilli population since it was detected in 9 women
supplemented with VSL#3 and 2 control women, corre-
sponding to a frequency of occurrence of 40.7%. Not-
ably, a general decrease in the intensity of L. helveticus
band was observed in P group while no variations were
appreciable in C group.
Cluster analysis showed that Lactobacillus-specific
DGGE profiles related to the time points W33 and W37
were closely related for all control women and for the
majority of women administered with VSL#3, except for
the subjects N. 1 and 15 (Figure 2).Quantitative variations of vaginal bacterial populations
Quantitative real-time PCR (qPCR) was performed to
analyze changes in concentration of Lactobacillus, Bifi-
dobacterium and Streptococcus thermophilus, that were
included in the probiotic VSL#3, and Gardnerella vagi-
nalis, Atopobium, Prevotella and Veillonella, that are im-
portant BV-related genera and species [22,28]. qPCR
efficiency for all assays was between 90% and 110% and
correlation coefficients for genomic DNA standards
were > 0.99. The sensitivity of qPCR assays was 9.1 ×


































































































































































































































































































































































































Figure 2 (See legend on next page.)
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Figure 2 PCR-DGGE analysis with Lactobacillus-specific primers. Analysis was conducted on the vaginal samples collected at 33rd (W33) and
37th (W37) week of gestation from 15 women supplemented with the probiotic VSL#3 [(P) N. 1–15] and 12 control women [(C) N. 16–27]. N:
woman number; W: week of gestation; T: type of supplementation. (A) PCR-DGGE fingerprints. M, external reference marker. Band L16
corresponds to L. helveticus (GenBank accession number: AB571603) (B) Dendrogram of the DGGE profiles shown in panel A. Pearson correlation
was used to calculate the similarity in DGGE profiles.
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http://www.biomedcentral.com/1471-2180/12/236× 10-4, 3.3 × 10-1 ng of target DNA for Lactobacillus,
Bifidobacterium, S. thermophilus, G. vaginalis, Atopo-
bium, Prevotella and Veillonella, respectively. All sub-
jects naturally harbored strains belonging to
Lactobacillus, Bifidobacterium, Atopobium and Prevo-
tella, as demonstrated by the presence of these genera
in the vaginal samples collected at W33. Woman N. 9
(P group) was the only exception lacking lactobacilli at
both the baseline and after one-month intake of
VSL#3 (Table 2). G. vaginalis was found in two
women belonging to C group (N. 18 and 20) at both
time points at the concentration of 5.5 × 101 ± 3.8 (N.
18: W33), 7.5 × 101 ± 4.6 (N. 18: W37), 2.2 × 102 ±
1.8 × 101 (N. 20: W33) and 1.9 × 102 ± 3.2 × 101 (N.
20: W37). S. thermophilus and Veillonella were not
detected in any pregnant woman enrolled in this study.
Statistical elaboration of qPCR data related to Lactoba-
cillus, Bifidobacterium, Atopobium and Prevotella was
performed to search for significant variations of these
genera associated with the going on of pregnancy or the
probiotic supplementation (Figure 3). No significant
changes in the amounts of these bacteria were found
between W33 and W37 in both P and C groups. How-
ever, in spite of the lack of statistical relevance, a weak
modulation was observed for Bifidobacterium and Ato-
pobium. Regarding bifidobacteria (Figure 3B), a physio-
logical tendency to decrease was observed in vaginal
samples of control women at the end of the study period
(mean value, W33: 4.3 ± 2.2 × 10-1; W37: 2.0 ± 1.7 ×
10-1). This trend seemed to be counterbalanced in
women consuming VSL#3 since amount of bifidobac-
teria slightly increased during the supplementation
period (mean value, W33: 9.9 × 10-1 ± 1.6 × 10-1; W37:
1.4 ± 1.2 × 10-1). An opposite trend was observed for
Atopobium (Figure 3C). This genus increased at W37
(mean value, 9.2 ± 3.2) compared to W33 (mean value,
7.0 ± 2.8) in C group, while it remained constant after
VSL#3 supplementation (mean value, W33: 1.4 × 101 ±
3.8; W37: 1.3 × 101 ± 5.2).Immunological profiles
The effect of the probiotic intake on the vaginal immune
response was evaluated by measuring the levels of 27
cytokines, chemokines and growth factors in the vaginal
samples of the pregnant women belonging to P and C
groups.Figure 4 shows the cytokines and chemokines whose
concentration significantly changed in P and C groups
during the study period (P < 0.05). In group C, signifi-
cant reductions at W37 were found for 5 mediators, 4
cytokines [IL-4 (mean value, W33: 2.8 × 10-2 ± 1.5 ×
10-2; W37: 1.3 × 10-2 ± 6.9 × 10-3), IL-7 (mean value,
W33: 1.2 × 10-1 ± 8.6 × 10-2; W37: 6.1 × 10-2 ± 3.5 ×
10-2), IL-9 (mean value, W33: 1.1 ± 5.6 × 10-1; W37: 3.7
× 10-1 ± 1.5 × 10-1) and IL-10 (mean value, W33: 1.5 ×
10-1 ± 1.1 × 10-1; W37: 9.4 × 10-2 ± 5.4 × 10-2)] and 1
chemokine [RANTES (mean value, W33: 4.3 ± 2.9;
W37: 1.3 ± 3.9 × 10-1)]. Both IL-4 and IL-10 are pro-
duced by Th2 cells and exert a regulatory role in the im-
mune response. IL-7 and IL-9 are hematopoietic growth
factors that control proliferation and homeostasis of a
variety of hematopoietic cells. RANTES is a pro-
inflammatory chemokine which attracts monocytes, lym-
phocytes, basophils and eosinophils in the inflammatory
response. In P group a significant variation was regis-
tered only for the chemokine Eotaxin, which decreased
after probiotic supplementation (mean value, W33: 5.3
± 8.8; W37: 2.0 ± 2.1). Eotaxin exerts a pro-
inflammatory activity by recruiting eosinophils during
allergic responses.
Figure 5 shows women, belonging to P and C groups,
who registered significant variations in total levels of
immune-mediators during the study period (P < 0.05).
Significant changes were found for women N. 18, 19, 20,
21, 23, 24, 25 and 27 (8/12; 67%) of C group and women
N. 1, 2, 3, 10, 11 (5/15; 33%) of P group.Discussion
To our knowledge, this is the first study describing the
effect of a probiotic mixture, orally consumed during the
last trimester of pregnancy, on the vaginal microbiota
and immune response. Although several health-
promoting activities of probiotics have been described in
relation to the gut homeostasis [16,32], less information
is available regarding the interactions between orally
administered probiotic bacteria and the vaginal micro-
bial habitat.
The first step in ascertaining the influence of the dietary
supplementation with the probiotic VSL#3 on the vaginal
microbiota of pregnant women was the characterization
of vaginal bacterial communities by using an integrated
approach based on PCR-DGGE and qPCR.
Table 2 qPCR data of Lactobacillus, Bifidobacterium, Atopobium and Prevotella
ng of target DNA/μg vaginal genomic DNA (mean ± SD)
Woman N. Time point Lactobacillus Bifidobacterium Atopobium Prevotella
Probiotic (P)
1 W33 2.4 × 101 ± 1.1 1.9 × 10-2 ± 7.4 × 10-3 3.6 ± 1.5 2.1 × 10-2 ± 1.0 × 10-2
W37 3.0 × 101 ± 3.1 3.1 × 10-2 ± 2.7 × 10-4 1.3 × 101 ± 6.8 9.1 × 10-2 ± 1.6 × 10-2
2 W33 9.6 ± 8.7 × 10-1 3.1 × 10-2 ± 8.8 × 10-3 5.4 × 101 ± 7.4 1.4 × 10-1 ± 4.8 × 10-2
W37 5.9 × 10-1 ± 4.9 × 10-2 2.4 × 10-2 ± 1.2 × 10-2 2.4 × 101 ± 1.9 × 101 1.1 × 10-1 ± 1.1 × 10-2
3 W33 2.4 × 101 ± 2.9 2.4 × 10-2 ± 4.2 × 10-3 1.1 × 101 ± 6.0 1.1 × 10-1 ± 7.7 × 10-3
W37 2.2 × 101 ± 2.4 3.0 × 10-2 ± 2.4 × 10-3 4.0 ± 2.3 5.2 × 10-2 ± 8.2 × 10-3
4 W33 2.2 × 101 ± 2.0 6.8 × 10-2 ± 8.3 × 10-3 4.7 ± 1.9 7.3 × 10-2 ± 2.9 × 10-2
W37 1.5 × 101 ± 1.4 2.1 × 10-2 ± 7.2 × 10-3 5.2 ± 2.0 4.6 × 10-2 ± 9.5 × 10-3
5 W33 2.5 × 101 ± 4.5 2.1 × 10-2 ± 3.4 × 10-3 1.2 × 101 ± 3.0 9.3 × 10-2 ± 8.3 × 10-3
W37 2.2 x 101 ± 4.5 1.4 x 10-2 ± 3.2 x 10-3 1.5 x 101 ± 1.9 3.0 x 10-2 ± 1.1 x 10-2
6 W33 1.1 × 10-1 ± 3.4 × 10-3 7.1 × 10-2 ± 7.1 × 10-3 1.0 × 101 ± 4.1 1.2 × 10-1 ± 1.3 × 10-2
W37 2.2 ± 6.0 × 10-1 2.1 ± 1.7 × 10-1 2.4 × 101 ± 1.0 × 101 1.5 × 10-1 ± 1.2 × 10-2
7 W33 4.1 × 101 ± 8.5 3.7 × 10-2 ± 5.4 × 10-3 2.9 × 101 ± 9.2 1.2 × 10-1 ± 2.1 × 10-2
W37 2.0 × 101 ± 2.6 1.7 × 10-2 ± 4.4 × 10-3 2.6 × 101 ± 7.7 1.1 × 10-1 ± 1.1 × 10-3
8 W33 1.0 × 101 ± 1.7 × 10-1 1.3 × 10-2 ± 1.9 × 10-3 5.5 ± 1.2 4.2 × 10-2 ± 1.9 × 10-2
W37 2.1 × 101 ± 2.0 1.5 × 10-2 ± 2.6 × 10-3 1.6 × 101 ± 6.6 5.1 × 10-2 ± 3.3 × 10-3
9 W33 0.0 ± 0.0 7.1 × 10-3 ± 2.8 × 10-5 1.8 × 101 ± 7.1 6.7 × 10-2 ± 1.5 × 10-2
W37 0.0 ± 0.0 1.1 × 101 ± 1.0 1.5 × 101 ± 6.8 2.3 × 10-1 ± 8.0 × 10-2
10 W33 6.7 ± 6.1 × 10-1 2.0 × 10-2 ± 4.8 × 10-3 1.4 × 101 ± 4.3 8.6 × 10-2 ± 2.0 × 10-2
W37 1.1 × 101 ± 1.4 2.3 × 10-2 ± 1.5 × 10-2 1.7 × 101 ± 9.7 8.0 × 10-2 ± 2.9 × 10-2
11 W33 2.7 × 101 ± 1.7 2.9 x 10-3 ± 1.7 × 10-3 2.3 ± 1.8 3.2 × 10-2 ± 3.3 × 10-3
W37 3.0 × 101 ± 5.6 1.3 x 10-2 ± 8.5 × 10-3 1.3 ± 7.5 × 10-1 3.6 × 10-2 ± 1.3 × 10-2
12 W33 2.2 ± 5.6 × 10-1 1.5 × 101 ± 2.3 1.4 × 101 ± 2.9 2.2 × 10-1 ± 2.1 × 10-2
W37 2.0 ± 3.1 × 10-1 8.7 ± 5.6 × 10-1 1.2 × 101 ± 2.3 1.0 × 10-1 ± 1.8 × 10-2
13 W33 3.7 × 101 ± 5.4 3.0 × 10-2 ± 4.5 × 10-3 7.0 ± 2.6 × 10-1 2.7 × 10-2 ± 5.0 × 10-4
W37 6.6 × 101 ± 5.9 1.1 × 10-2 ± 2.2 × 10-3 6.8 ± 6.6 × 10-1 5.7 × 10-2 ± 2.0 × 10-3
14 W33 2.2 × 101 ± 8.5 1.7 × 10-2 ± 4.9 × 10-3 9.0 ± 4.4 × 10-1 6.7 × 10-2 ± 6.6 × 10-3
W37 1.6 × 101 ± 4.9 2.8 × 10-2 ± 4.7 × 10-3 1.1 × 101 ± 1.1 1.1 × 10-1 ± 1.8 × 10-3
15 W33 2.2 × 101 ± 7.1 1.4 × 10-2 ± 7.1 × 10-3 1.8 × 101 ± 5.6 1.1 × 10-1 ± 1.4 × 10-2
W37 2.8 × 101 ± 3.4 4.7 × 10-3 ± 2.3 × 10-3 1.1 × 101 ± 2.4 × 10-1 7.4 × 10-2 ± 2.4 × 10-3
Control (C)
16 W33 5.4 × 101 ± 4.0 2.1 × 10-2 ± 5.6 × 10-3 1.1 × 101 ± 4.6 6.8 × 10-2 ± 1.1 × 10-2
W37 2.0 × 101 ± 1.7 2.0 × 10-2 ± 7.4 × 10-3 1.4 × 101 ± 5.0 5.6 × 10-2 ± 5.4 × 10-3
17 W33 5.5 ± 5.3 × 10-1 6.0 ± 1.6 × 10-1 1.2 × 101 ± 4.3 5.9 × 10-2 ± 2.3 × 10-2
W37 1.5 × 101 ± 2.9 9.3 ± 5.3 × 10-1 1.9 × 101 ± 8.7 5.4 × 10-2 ± 1.0 × 10-2
18 W33 2.6 ± 1.6 × 10-1 1.8 ± 3.5 × 10-2 1.3 × 101 ± 5.5 8.8 × 10-2 ± 1.7 × 10-2
W37 1.2 × 101 ± 2.0 2.9 ± 7.5 × 10-2 3.3 × 101 ± 4.4 4.5 × 10-2 ± 2.8 × 10-3
19 W33 7.6 × 101 ± 3.3 × 10-1 1.2 ± 7.9 × 10-3 1.3 × 101 ± 3.6 1.9 × 10-1 ± 3.2 × 10-3
W37 2.7 × 101 ± 3.8 2.7 × 10-2 ± 4.7 × 10-3 8.2 ± 4.6 1.1 × 10-1 ± 2.6 × 10-2
20 W33 1.6 × 101 ± 1.4 1.1 × 101 ± 1.2 1.2 × 101 ± 5.5 8.6 × 10-2 ± 1.5 × 10-2
W37 1.0 × 101 ± 6.4 × 10-2 1.1 × 101 ± 1.4 1.2 × 101 ± 4.7 1.1 × 10-1 ± 3.1 × 10-2
21 W33 5.6 × 101 ± 8.3 1.7 × 10-2 ± 1.7 × 10-3 2.1 × 101 ± 1.0 × 101 1.3 × 10-1 ± 2.0 × 10-2
W37 6.4 × 101 ± 1.5 3.3 × 10-2 ± 8.7 × 10-3 2.2 × 101 ± 1.0 × 101 1.2 × 10-1 ± 2.4 × 10-2
22 W33 4.3 × 101 ± 2.0 1.2 × 10-1 ± 2.8 × 10-2 2.3 × 10-1 ± 1.5 × 10-2 0.0 ± 0.0
W37 6.8 × 101 ± 5.1 2.7 × 10-2 ± 6.6 × 10-3 1.9 × 10-1 ± 2.0 × 10-2 0.0 ± 0.0
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Table 2 qPCR data of Lactobacillus, Bifidobacterium, Atopobium and Prevotella (Continued)
23 W33 2.6 × 101 ± 5.6 2.3 × 10-1 ± 3.6 × 10-2 0.0 ± 0.0 0.0 ± 0.0
W37 6.3 × 101 ± 2.0 8.2 × 10-3 ± 1.9 × 10-3 1.6 × 10-1 ± 2.9 × 10-2 5.3 × 10-1 ± 1.8 × 10-1
24 W33 1.2 × 101 ± 1.0 2.7 × 101 ± 2.1 × 10-1 1.8 ± 1.5 × 10-1 6.8 × 10-1 ± 3.4 × 10-2
W37 7.5 × 101 ± 3.8 9.7 × 10-3 ± 3.7 × 10-3 3.7 × 10-1 ± 3.4 × 10-2 0.0 ± 0.0
25 W33 6.5 × 101 ± 1.0 × 101 3.0 × 10-2 ± 1.0 × 10-2 7.5 × 10-2 ± 7.5 × 10-3 0.0 ± 0.0
W37 6.6 × 101 ± 7.1 9.1 × 10-3 ± 5.1 × 10-4 2.5 × 10-1 ± 2.7 × 10-2 0.0 ± 0.0
26 W33 8.5 × 101 ± 6.3 4.4 ± 9.3 × 10-1 3.2 × 10-1 ± 3.9 × 10-2 0.0 ± 0.0
W37 5.4 × 101 ± 4.5 2.0 × 10-2 ± 6.1 × 10-4 3.6 × 10-1 ± 4.2 × 10-2 0.0 ± 0.0
27 W33 7.0 × 101 ± 1.5 × 101 3.3 × 10-2 ± 4.7 × 10-3 2.8 × 10-1 ± 2.6 × 10-2 0.0 ± 0.0
W37 6.6 × 101 ± 3.6 × 10-1 2.1 × 10-2 ± 1.6 × 10-2 4.0 × 10-1 ± 3.8 × 10-2 0.0 ± 0.0
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sal primers for bacteria and Lactobacillus-specific pri-
mers, allowed us to investigate the variations of the
predominant vaginal bacterial communities and Lacto-
bacillus species occurring both physiologically in the last
trimester of pregnancy and potentially associated with
VSL#3 intake. The influence of the probiotic intake in
modulating the predominant bacterial populations and
Lactobacillus species could be hypothesized since signifi-
cant differences between DGGE profiles at W33 and
W37 were found only in women belonging to P group.
Notably, the lower percentage of women belonging to P
group who displayed significant differences in Lactoba-
cillus-specific DGGE profiles between W33 and W37,
compared to the universal bacterial DGGE patterns, sug-
gested a major stability of lactobacilli population and a
more extended impact of the probiotic VSL#3 on total
bacteria than lactobacilli. However, no significant
changes in single species abundances were found be-
tween W33- and W37-related universal DGGE profiles.
Differently, the statistical analysis of the peak heights of
the Lactobacillus-specific DGGE densitometric curves
allowed us to identify a band, corresponding to L. helve-
ticus, which significantly decreased after probiotic sup-
plementation. Strains belonging to L. helveticus are used
as starter cultures in the manufacturing of a variety of
fermented dairy products, to modulate flavor. The pres-
ence of L. helveticus in vagina, likely due to the migra-
tion from the gut, can be related to a diet rich in yogurt
and cheese. This work is not the first describing L. helve-
ticus in vaginal samples. Stoyancheva et al. [33] identi-
fied this species among several Lactobacillus isolates
from vaginal fluids of healthy Bulgarian women in child-
bearing age by using three different molecular techni-
ques, amplified ribosomal DNA restriction analysis,
ribotyping and PCR with species-specific primers. The
decrease of L. helveticus observed in our study could be
due to a competition between the Lactobacillus strains
present in VSL#3 formula and dairy L. helveticus strains
in colonizing vaginal environment.Cluster analysis showed that universal and Lactobacillus-
specific DGGE profiles related to the time points W33
and W37 of the control women were closely related.
Also the DGGE patterns of the majority of women admi-
nistered with VSL#3 grouped according to the subject
and not to the time point, revealing that the inter-
individual variability was higher than variability induced
by the probiotic supplementation.
The hypothesis of a positive action of VSL#3 on the
vaginal microbiota of pregnant women was further sup-
ported by qPCR results, which suggested a role of the
probiotic product in counteracting the decrease of the
health-promoting Bifidobacterium genus and the in-
crease of the BV-related Atopobium genus, that occurred
in control women during late pregnancy. Notably, group
B Streptococcus, which was found in two women (N.1
and 10) before the probiotic intake, was no longer found
after the dietary supplementation (data not shown).
The second step of the present research was the in-
vestigation of the vaginal immunological profiles of the
pregnant women in order to search for correlations be-
tween the VSL#3 intake and changes in vaginal immune
response. Pregnancy has been referred to as a state of
relative immune compromise. This notion has been
related to both demonstration of depression of certain
aspects of cell-mediated immunity and clinical observa-
tions of an increased severity of numerous infectious
conditions in pregnant women [7]. On the other hand,
preterm cervical ripening can be likened to an inflam-
matory process with cytokines as important mediators
[34].
Bioplex immunoassay was used in the present work to
measure levels of 27 cytokines, chemokines and growth
factors in the vaginal samples of the pregnant women
belonging to P and C groups. In group C a significant
reduction at W37 was found for IL-4, IL-7, IL-9, IL-10
and RANTES. IL-4 is a key regulator in humoral and
adaptive immunity. It has many biological roles, includ-
ing the stimulation of activated B-cells and T-cell prolif-





Figure 3 qPCR evaluation of Lactobacillus (A), Bifidobacterium
(B), Atopobium (C) and Prevotella (D). Analysis was performed on
vaginal samples collected at 33rd (W33) and 37th (W37) week of
gestation from pregnant women supplemented (P) and not
supplemented (C) with VSL#3. Data are expressed as ng of DNA of
the target genus per μg of total bacterial DNA extracted from the
vaginal sample. The diagrams show the mean values with error bars
representing the standard deviations.
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http://www.biomedcentral.com/1471-2180/12/236cells. A regulatory role is also exerted by IL-10. In rela-
tion to pregnancy, IL-10 decreases the production of
pro-inflammatory cytokines, such as IL-8, IL-6, TNFα,
IL-1β and prostaglandin E2 in lipopolysaccharide-
stimulated fetal membranes [35,36]. Both IL-4 and IL-
10 are produced by Th2 cells. IL-7 and IL-9 are
hematopoietic growth factors that act as regulators of
cell survival, proliferation and homeostasis of a variety
of hematopoietic cells. RANTES is a potent and versa-
tile chemokine, capable of attracting monocytes, lym-
phocytes, basophils and eosinophils. This cytokine has
been implicated in the regulation of the inflammatory
response and recruitment of macrophages to the im-
plantation site in early pregnancy [37]. However, no
variations in RANTES levels have been associated with
preterm cervical ripening and labor [34]. Immuno-
logical profiles related to women belonging to C group
indicated that some fluctuations in vaginal immune-C
P
Figure 4 Cytokines and chemokines whose concentration
significantly changed during the study period (P < 0.05). P,
probiotic group; C, control group; W33, 33rd gestational week (black
colour); W37, 37th gestational week (grey colour). Cytokine or
chemokine names are reported in x-axis. Data are expressed as pg
of the target cytokine or chemokine per μg of total proteins present
in the vaginal sample (y-axis). The diagrams show means with error
bars representing the standard deviations.
CP
Figure 5 Women registering significant variations in total levels
of immune-mediators. P, probiotic group; C, control group; W33,
33rd gestational week (black colour); W37, 37th gestational week
(grey colour). Identification numbers of women registering
significant variations are reported in x-axis. Data are expressed as pg
of total immune-mediators per μg of total vaginal proteins (y-axis).
The diagrams show means with error bars representing the standard
deviations.
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mester of pregnancy. In particular, it is noteworthy the
decrease of IL-10 and IL-4, important regulatory cyto-
kines controlling the inflammatory reaction responsible
for uterine contractions and cervical ripening at the
labor time [12]. In P group a significant variation was
registered only for the chemokine Eotaxin, which
decreased after probiotic supplementation. Eotaxin se-
lectively recruits eosinophils, and for this reason is
implicated in allergic responses [38]. By comparing the
data related to the two study groups, the following hy-
potheses could be formulated regarding the possible im-
pact of the probiotic intake on cytokine secretion during
late pregnancy: (i) probiotics counteracted the decrease
of anti-inflammatory cytokine levels occurring in C
group; (ii) probiotics induced the decrease of a pro-
inflammatory cytokine in P group, showing a global
anti-inflammatory effect on the vaginal immunity. In
addition, a stabilization effect on the vaginal immunityduring late pregnancy could be attributed to the pro-
biotic intake, since the percentage of women with modi-
fied amounts of immune-mediators decreased from 67%
to 31% in relation to the dietary supplementation.
Conclusion
The impact of the oral intake of the probiotic VSL#3 on the
vaginal microbiota and immune response of pregnant
women was investigated by molecular fingerprinting tech-
niques (PCR-DGGE and qPCR) and LuminexW immuno-
assay. The major findings of this study are the following: (i)
VSL#3 intake seems to be associated with a modulation of
the predominant vaginal bacterial communities; (ii) VSL#3
modulation of Lactobacillus population appears to be
related to variations of L. helveticus species; (iii) a potential
role of the probiotic product in counteracting the physio-
logical decrease of Bifidobacterium and increase of Atopo-
bium could be hypothesized; (iv) the probiotic
supplementation can be associated with a global anti-
inflammatory effect on the vaginal immunity, with potential
implications in preventing preterm birth.
Methods
Study design and sample collection
A pilot, not randomized, controlled and perspective
study was conducted. The study protocol was approved
by the ethical committee of the University of Bari, Italy.
Written informed consent was obtained from all the par-
ticipants in the study. A total of 27 healthy pregnant
women (21 to 42 years of age; mean, 32) who had no
symptoms of vaginal or urinary tract infection were
included in the present study (Table 3). None of the sub-
jects had received oral or local antimicrobial therapy
within the previous 2 weeks. The recruited subjects were
divided into 2 groups: (i) probiotic group [P (n=15)];
(ii) control group [C (n=12)] on the basis of their avail-
ability to consume the probiotic product. Women of the
P group consumed 1 sachet once/day of VSL#3 (VSL
Pharmaceuticals, Inc.,Towson, MD, USA) for 4 weeks
from the 33rd (W33) to the 37th (W37) week of gesta-
tion. Women of the C group did not receive any dietary
supplementation. VSL#3 sachet contains 900 billion vi-
able lyophilized bacteria consisting of 4 strains of Lacto-
bacillus (L. paracasei, L. plantarum, L. acidophilus, L.
delbrueckii subsp. bulgaricus), 3 strains of Bifidobacter-
ium (B. longum, B. breve, B. infantis) and 1 strain of
Streptococcus thermophilus. Mid-vaginal swabs were col-
lected from women of both P and C groups at the time
points W33 and W37. Samples were placed in 1 ml of
sterile saline and stored immediately at −80°C until use.
The individual characteristics (age, type of delivery and ges-
tational age at birth) of women enrolled in the present study
are reported in Table 3. Gestational age was determined by
utilizing the last menstrual period and earliest ultrasound.
Table 3 Characterization of the subjects included in the
study groups
Woman N Age Type of delivery1 Gestational age at birth
Probiotic (n = 15)
1 31 SD 39 week + 6 days
2 32 CD 40 week + 3 days
3 39 SD 40 week + 1 day
4 31 SD 40 week + 2 days
5 33 SD 40 week + 3 days
6 30 SD 39 week
7 33 SD 41 week + 3 days
8 34 CD 39 week
9 36 CD 38 week + 4 days
10 38 SD 38 week + 5 days
11 42 SD 39 week + 4 days
12 30 SD 39 week
13 29 SD 40 week + 2 days
14 33 CD 39 week + 2 days
15 25 SD 40 week + 1 day
Control (n = 12)
16 28 SD 40 week + 6 days
17 33 SD 39 week + 3 days
18 33 CD 37 week + 4 days
19 32 CD 41 week + 3 days
20 34 SD 40 week
21 21 SD 39 week + 5 days
22 30 SD 38 week + 6 days
23 30 SD 40 week + 2 days
24 34 CD 39 week + 6 days
25 38 CD 41 week + 1 days
26 38 CD 38 week + 5 days
27 30 SD 40 week + 2 days
1 SD: spontaneous delivery; CD: caesarean delivery.
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Frozen vaginal swabs were thawed, mixed by vortex shaker
for 1 min and then removed from the liquid. The liquid was
centrifuged at 10,000 × g for 15 min, and the pellet was
washed 3 times in saline at 40°C. The pellet was resus-
pended in 180 μl of enzymatic lysis buffer (20 mM Tris–
HCl, pH 8, 2 mM EDTA, 1.2% Triton X-100, 20 mg/ml
lysozyme) and incubated at 37°C for 30 min. Glass beads
(200 mg) were added and the sample was mixed by vortex-
ing for 1 min. Total DNA was extracted by using the
DNeasy Blood & Tissue Kit (Qiagen, Hilden, Germany) fol-
lowing the protocol “Pretreatment for Gram-positive bac-
teria”. A slight modification was introduced: a centrifugation
step (8000 × g for 5 min) was carried out after incubation
with proteinase K to remove glass beads. DNA amountswere quantified by using NanoDrop 1000 (Thermo Scien-
tific, Wilmington, DE).
PCR-DGGE and cluster analysis
Amplification reactions were performed in a Biometra Ther-
mal Cycler T Gradient (Biometra, Göttingen, Germany).
GoTaq Flexi DNA Polymerase (Promega, Madison, WI) was
used as thermostable DNA polymerase. The reaction mix-
ture contained 0.5 μM of each primer, 200 μM of each
dNTP, 2 mM MgCl2 solution, 1.25 U of GoTaq Flexi DNA
Polymerase, 5 μl of Green GoTaq Flexi buffer 5X, and 2 μl
of the bacterial DNA template (30–40 ng) in a final volume
of 25 μl. The universal primers HDA1-GCclamp and HDA2
for bacteria [39] were used to amplify a conserved region
within the 16S rRNA gene. The thermocycle program con-
sisted of the following time and temperature profile: 95°C
for 5 min; 30 cycles of 95°C for 30 s, 56°C for 30 s, 72°C for
60 s; and 72°C for 8 min. The Lactobacillus genus-specific
primers Lac1 and Lac2-GCclamp [40] were used to amplify
a specific region of the 16S rRNA gene of lactobacilli. The
amplification program was 95°C for 5 min; 35 cycles of 95°C
for 30 s, 61°C for 30 s, 72°C for 60 s; and 72°C for 8 min. A
volume of 8 μl of PCR samples was loaded on DGGE gels,
containing 30-50% and 25-55% gradients of urea and forma-
mide for universal bacteria and lactobacilli, respectively.
DGGE analysis was performed by using the D-Code Univer-
sal Mutation System Apparatus (Bio-Rad, Los Angeles, CA),
as previously described [22]. Following electrophoresis, gels
were silver stained [41] and scanned using a Molecular
Imager Gel Doc XR System (Bio-Rad). DGGE gel images
were analyzed using the FPQuest software version 4.5 (Bio-
Rad). In order to compensate for gel-to-gel differences and
external distortion to electrophoresis, the DGGE patterns
were aligned and normalized using an external reference
marker. The marker for the DGGE analysis with the
universal primers for bacteria contained PCR amplicons
from Bacteroides, Coriobacterium, Enterococcus faecalis,
Bifidobacterium bifidum, Lactobacillus casei, Acidaminococ-
cus fermentas and Atopobium. The marker for the DGGE
analysis with Lactobacillus-specific primers contained PCR
amplicons from L. plantarum, L. paracasei, L. brevis, L. gas-
seri, L. acidophilus and L. delbrueckii subsp. bulgaricus.
After normalization, bands were defined for each sample
using the appropriate densitometric curve. The similarity in
the profiles was calculated on the basis of the Pearson cor-
relation coefficient with the Ward clustering algorithm.
Cluster analysis of the DGGE patterns was performed using
the FPQuest software.
Sequencing of DGGE fragment
The DNA fragment of interest was excised from the de-
naturing gel with a sterile scalpel, washed once in 1X
PCR buffer, and incubated in 20 μl of the same buffer
overnight at 4°C. Two μl of the buffer solution were
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the 16S rRNA region was conducted as described above
by employing the primers Lac1 and Lac2 (without the
GC-clamp). The re-amplified fragment was purified
using the Wizard SV Gel and PCR Clean-up system
(Promega), and then subjected to automated sequence
analysis of both DNA strands with Lac1 and Lac2. Big-
Dye terminators (ABI-PerkinElmer, Foster City, CA)
were used with a 377 sequencer (ABI). Sequence identity
was determined by comparison with the rRNA gene
sequences deposited in GenBank database using BLAST
algorithm (www.ncbi.nlm.nih.gov/BLAST).
Quantitative real-time PCR
Quantitative PCR was performed in a LightCycler in-
strument (Roche, Mannheim, Germany) and SYBR
Green I fluorophore was used to correlate the amount of
PCR product with the fluorescence signal. Each DNA
sample was amplified with different genus- or species-
specific primer sets targeted to 16S rRNA gene or 16S-
23S rRNA spacer region: Bact-0011f/Lab-0677r [42] for
Lactobacillus, Bif164/Bif662 [43] for Bifidobacterium,
Th1/Th2 [44] for Streptococcus thermophilus, F-GV1/R-
GV3 [45] for Gardnerella vaginalis, c-Atopo-f/c-Atopo-r
[46] for Atopobium, g-Prevo-f/g-Prevo-r [47] for Prevo-
tella, VeilloF/VeilloR [48] for Veillonella. Amplifications
were carried out in a final volume of 20 μl containing
0.5 μM of each primer, 4 μl of LightCycler-FastStart
DNA Master SYBR Green I (Roche) and either 2 μl of
template or water (no-template control).
The thermal cycling conditions were as follows: an
initial denaturation step at 95°C for 10 min followed by
30 (Lactobacillus, Atopobium, G. vaginalis and Veillo-
nella), 35 (Prevotella) or 40 (Bifidobacterium, S. thermo-
philus) cycles of denaturation at 95°C for 15 s; primer
annealing at 63°C (Lactobacillus, S. thermophilus), 62°C
(Veillonella), or 60°C (Bifidobacterium, Atopobium, Pre-
votella, G. vaginalis ) for 20 s; extension at 72°C for 45
s (Lactobacillus, Atopobium, Prevotella, G. vaginalis,
Veillonella), 30 s (Bifidobacterium), or 15 s (S. thermo-
philus) and a fluorescence acquisition step at 85°C
(Lactobacillus, Atopobium, G. vaginalis, Veillonella,
S. thermophilus), 87°C (Prevotella) or 90°C (Bifidobac-
terium) for 5 s. DNAs extracted from L. acidophilus
NCFM, B. longum NCC2705, G. vaginalis ATCC 14018,
Prevotella bivia ATCC 29303, Veillonella parvula ATCC
10790, Atopobium vaginae ATCC BAA-55 and S. ther-
mophilus ATCC 19258 were used as standards for PCR
quantification. DNAs extracted from vaginal samples
were amplified in triplicate for each primer set and the
mean value was used for statistical analysis. Data were
expressed as ng of DNA of the targeted genus or spe-
cies per μg of total DNA extracted from the vaginal
sample.Bioplex immunoassay
Cytokine levels were determined using a multiplexed
bead immunoassay. Prior to assay, vaginal samples were
concentrated 10 times with Microcon spin devices
(YM3, Millipore Corporation, Billerica, MA) and subse-
quently resuspended in Bio-Plex Assay Buffer. The
levels of 27 immune-mediators, 15 cytokines (IL-1β, IL-
1ra, IL-2, IL-4, IL-5, IL-6, IL-7, IL-9, IL-10, IL-12(p70),
IL-13, IL-15, IL-17, IFN-γ, TNFα), 7 chemokines (MCP-
1, MIP-1α, MIP-1β, RANTES, Eotaxin, IL-8, IP-10) and
5 growth factors (PDGF-BB, FGF basic, G-CSF, GM-
CSF, VEGF), were measured using the human ultrasen-
sitive cytokine 27-plex antibody bead kit (Bio-Rad).
Assays were performed in 96-well filter plates, as previ-
ously described [49]. Briefly, the filter plate was pre-
wetted with washing buffer (Bio-Rad) and the solution
was aspirated from the wells using a vacuum manifold
(Millipore Corporation). Microsphere beads coated with
monoclonal antibodies against the different target ana-
lytes were added to the wells. Samples and standards
were pipetted into the wells and incubated for 30 min
with the beads. Wells were washed using a vacuum
manifold (Millipore Corporation) and biotinylated sec-
ondary antibodies were added. After incubation for 30
min, beads were washed then incubated for 10 min with
streptavidin-PE conjugated to the fluorescent protein,
R-phycoerythrin (streptavidin/R-phycoerythrin). After
washing to remove the unbound streptavidin/R-phyco-
erythrin, the beads (a minimum of 100 per analyte) were
analyzed in the Luminex 200 instrument (MiraiBio,
Alameda, CA). The Luminex 200 monitors the spectral
properties of the beads to distinguish the different ana-
lytes, while simultaneously measuring the amount of
fluorescence associated with R-phycoerythrin, reported
as median fluorescence intensity. The concentration of
the samples was estimated from the standard curve
using a fifth-order polynomial equation and expressed
as pg/ml after adjusting for the dilution factor (Bio-Plex
Manager software version 5.0). Samples below the de-
tection limit of the assay were recorded as zero, while
samples above the upper limit of quantification of the
standard curves were assigned the highest value of the
curve. The intra-assay CV including ultrafiltration and
immunoassay averaged 19%. Concentrations of cyto-
kines, chemokines and growth factors were then con-
verted in pg of the target molecule per μg of total
proteins present in the vaginal sample.
Statistical analysis
Statistical analysis was performed using SigmaStat
(Systat Software, Point Richmond, CA). For each subject,
variations of the DGGE profiles related to the time
points W33 and W37 were analyzed by Pearson correl-
ation. Significant differences in the intensity of each
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amounts of the bacterial genera and species determined
by qPCR were searched by using Wilcoxon Signed Rank
Test. This test was also used to analyze differences in
cytokines, chemokines and growth factors. A P value
below 0.05 was considered statistically significant.
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